• Explore /
  • Poster
  • / Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.

Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.

Abstract Poster

Authors

null

Richard M. Stone

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Richard M. Stone , Robert Collins , Martin S. Tallman , Roland B. Walter , Chatchada Karanes , Prapti Arvind Patel , Madhuri Vusirikala , Catherine Callaghan Coombs , Gretchen Olson , Vinay Kumar Jain , Eunice S. Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT02283177

Citation

J Clin Oncol 35, 2017 (suppl; abstr 7016)

DOI

10.1200/JCO.2017.35.15_suppl.7016

Abstract #

7016

Poster Bd #

216

Abstract Disclosures

Similar Posters

First Author: Richard M. Stone

First Author: Adolfo Fuentes

First Author: Nicholas James Short

First Author: Eric Jay Feldman